News

Te Wairua (co-existing disorders – addictions + mental health) residential service in Royal Oak, great benefits and competitive salary package! Mon-Fri $78,020 - $86,174 salary (depending on experience) $7,000 annual position allowance + free meals + 22 days annual leave Monday to Friday, no evenings, no weekends! Registered Nurse – Te Wairua Royal Oak If you would like to make a positive difference and use your experience as a registered nurse, then join our Te Wairua (co-existing...

Colestyramine (Mylan) (Pharmacode: 2662000) Supplies may be limited from late May until July 2026. An alternative (Pharmacode: 2700026) was funded from 1 June and should be available from Orspec in early June. Kisqali (ribociclib): Storage changes Kisqali will once again be able to be stored at room temperature. More details and a flyer for patients are available on our website. Neocate Gold: Funding issue The Pharmacode for new look Neocate Gold was funded from 1 June. Oestradiol valerate...

Welcome to the latest update from the Ministry of Health | Manatū Hauora on the regulation of medicines, medical devices and natural health products. This edition provides information on the Government’s recent decision to regulate sunscreens and other policy matters under the Medical Products Bill (the Bill). This update also accompanies the proactive release of documents relating to those decisions. This newsletter contains information on the following: New policy decisions for the Bill · ...

There is currently a supply disruption affecting risperidone (Teva) 0.5 mg and 2 mg tablets. This is due to an issue at the manufacturer. To support continuity of care, from 1 June, Pharmac will list (fund) alternative products, Risperidone Sandoz 0.5 mg tab and Risperidone Sandoz 2 mg tab. Please note Risperidone Sandoz tablets are not Medsafe‑approved and must therefore be prescribed and supplied in accordance with Section 29A of the Medicines Act. Further information about this...

Re: Supply disruption: Colestyramine Powder for Oral Suspension (Sachet). There is a supply disruption affecting the currently listed Section 29 colestyramine oral sachets, Colestyramine – Mylan. From 1 June, Pharmac will list an alternative Section 29 product: Questran Light (Neon). This is not a Medsafe‑approved product and must be prescribed in accordance with Section 29 of the Medicines Act. As no Medsafe approved product is currently listed on the Schedule, Section 29A does not...

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 29 May 2026. It includes information on: New updates Resolved Supply Issues Supply Constraint – TruSteel Infusion Sets There is a global supply constraint affecting TruSteel infusion sets due to issues at a component supplier. This disruption is not specific to New Zealand and is likely to continue for the rest of 2026. It affects all four funded TruSteel infusion...